Compare · BSX vs SNWV
BSX vs SNWV
Side-by-side comparison of Boston Scientific Corporation (BSX) and SANUWAVE Health Inc. (SNWV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SNWV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $65.77B, about 1289.8x SNWV ($51.0M).
- Over the past year, BSX is down 58.2% and SNWV is down 83.4% - BSX leads by 25.2 points.
- SNWV has hit the wire 2 times in the past 4 weeks while BSX has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 2 for SNWV).
- Company
- Boston Scientific Corporation
- SANUWAVE Health Inc.
- Price
- $44.27+1.54%
- $5.95-0.83%
- Market cap
- $65.77B
- $51.0M
- 1M return
- -0.43%
- -30.49%
- 1Y return
- -58.17%
- -83.38%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 0
- 2
- Recent ratings
- 25
- 2
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Latest SNWV
- SANUWAVE Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance
- SEC Form 4 filed by Director Blizard Jeffrey
- SEC Form 4 filed by Director Miller Ian D.
- SEC Form 4 filed by Director Bazar Gregory Matthew
- SEC Form 4 filed by Director Tyler James
- SEC Form 4 filed by Chief Executive Officer Frank Morgan C.
- SANUWAVE Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Sanuwave Health Updates Second Quarter 2026 Guidance
- SANUWAVE Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders